TO 
FROM 
Dr. James B. Wyngaarden, Director 
National Institutes of Health 
9000 Rockville Pike 
Bethesda , MD 20205 
DONALD C. GARNER 
98 MAIN STREET. SUITE 216 
T1BURON. CA 94920 
(415) 435-2477 
(415) 435-1123 
SUBJECT RAC Approval of Rosenberg-Blaese-Anderson Project date 
Possibly it would be useful if I outlined the thinking 
behind the RAC approved motion I offered at the September 
meeting. First, I carefully structured the motion so that it was 
limited to ten patients each of whom would have a life expectancy 
of not to exceed 90 days. Second, there is a possibility, 
however remote, one or more of the ten patients could benefit 
from the information gained from the genetic labels they receive. 
Third, due to the tight guidelines contained in the RAC approved 
motion the results of the research will receive careful scrutiny 
from the scientific community before this highly visible 
procedure will be permitted to go beyond the initial restricted 
stage. Fourth, after extensive discussion it seemed we were 
attempting to pirouette on a molecule with nothing more to be 
achieved . 
MESSAGE 
cc: Jay Moskowitz 
Becky Ann Lawson 
SIGNED 
f~1 NO REPLY NECESSARY 
f~~l REPLY REQUESTED - USE REVERSE SIDE 
[452] 
Recombinant DNA Research, Volume 13 
